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Abstract
Background: Depression and anxiety are serious complications of cancer and deemed a challenging
diagnosis due to the symptoms of depression mimicking common side effects of chemotherapy and
radiation. Signs/symptoms frequently are underrecognized thus appropriate treatment is delayed,
compromising the health-related quality of life (HRQOL) for pediatric oncology patients.
Purpose: Analyze existing physician and Advanced Practice Provider (APP) clinical practice regarding
depression, via a pre- and post-survey and educational PowerPoint on the use of the Center for
Epidemiological Studies Depression Scale for Children (CES-DC) to promote early recognition of
depression.
Methods: A prospective, single-arm, study was completed in the Kentucky Children’s Hospital
DanceBlue Clinic (DBC). Surveys were distributed to physicians and APPs. Pre- and post-surveys via
Qualtrics along with an educational PowerPoint was used to analyze clinician knowledge, clinical
practice, and barriers.
Results: Out of twelve participants, eight completed the pre- and post-survey; four were Physicians and
four were APP. Following the educational PowerPoint, a statistically significant increase in perception of
the need to screen every patient with a standardized depression screening tool was observed (75%). A
majority were willing to make the practice change (75%), and most recommended the CES-DC (87.5%).
Conclusion: The results of this study warrant the need for the use of a standardized depression screening
tool, with the CES-DC as the preferred tool, in the pediatric oncology population. The future intentions to
screen every patient upon clinic visit and hospital admission could not be analyzed.
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Promotion of Early Recognition of Depression to Improve Health Related Quality of Life in
Pediatric Oncology Patients
Background and Significance
Introduction to Problem
Pediatric cancer is an emotionally devastating, life threatening, and feared diagnosis. The
treatments accompanying a cancer diagnosis along with the comprehensive understanding of the life
altering disease can be a heavy emotional and physical burden to both the patient and their family.
According to the American Cancer Society (2022), approximately 10,470 children younger than 15 will
be diagnosed with cancer in the United States in 2022. Fortunately, diagnostics and treatment
interventions have advanced dramatically in recent decades, resulting in a five year or more survival rate
in 85% of children with cancer (Langer et al., 2018). This is a significant increase from the 1980s when
only 65% of children had a five-year survival rate (Kaatsch, 2010). Despite cancer survival and remission,
evidence shows that transitioning back to typical child-like behaviors amongst peers is often a long and
difficult journey for pediatric patients, and many report overall decreased well-being (Kaplan et al.,
2013). Laypersons and oncologists now implicate psychological functioning in the prediction of cancer
outcomes. In consequence, the field of psycho-oncology has experienced exponential growth (Levin et
al., 2006).
Emotional distress is an indicator of suffering as well as a predictor of poor health and negative
quality of life among children and adolescents with cancer (Yardeni et al., 2021). Common illnesses such
as depression and anxiety are serious complications of cancer, but they are often neglected, compromising
the mental health of pediatric oncology patients and influencing their Health Related Quality of Life
(HRQOL), treatment adherence, survival rates, and long-term financial burden (Smith, 2015). Pediatric
psycho-oncologists deem depression a challenging diagnosis, as the symptoms of depression e.g.,
restlessness, decreased appetite, low energy level, fatigue, and altered neurological status can mimic the
common side effects of chemotherapy and radiation (Ruland et al., 2009).
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Context, Scope and Consequences
Depression is defined as a two-week period of depressed mood or the loss of interest of pleasure
in nearly all activities for most of the day nearly every day (APA, 2022). Symptoms are characterized as
lack of interest in daily activities, sad thoughts, melancholy behavior, changes in sleeping pattern, appetite
changes, irritability, suicidal ideation, thoughts of self-harm, and disinterest in the world around the
patient (APA, 2022). Cancer-related depression is a pathologic affective response to the loss of normalcy
because of a cancer diagnosis, treatment, or complication (Çavuşoğlu, 2001). Although depression
symptoms vary from mild to severe, it is treatable and when diagnosed early, it can be manageable with
pharmacotherapy and noninvasive methods such as psychotherapy (APA, 2022).
Children with cancer have a high risk for depression because they are living continuously with a
stressful and sometimes life-threatening illness (Çavuşoğlu, 2001). Long-term or high levels of
psychological stress activate the hypothalamus-pituitary-adrenal axis, causing a release of psychological
symptoms that warrant a depression diagnosis (Smith, 2015). Greater than 70% of oncologists and 85% of
cancer patients believe there is a strong correlation between mood and mental well-being on the
progression of cancer (Statin et al., 2009). Furthermore, the correlation between poor recognition of
depressive symptoms and the adherence to a cancer treatment regimen leads to nonadherence throughout
the cancer trajectory, decreased HRQOL, and survivorship (Pitman et al., 2018).
Depression does not discriminate; it can affect anyone regardless of their circumstances. Several
factors are known to play a role in depression including biochemistry, genetics, personality, and
environmental factors (APA, 2022). Few risk factors assumedly identified among pediatric cancer
patients are suggestive of depressive diagnostics, including self-blame for diagnosis, functional
limitations, body dysmorphia, and lessened autonomy (Else-Quest et al., 2009). Evidence suggests
integrating multidisciplinary depression interventions into cancer care as a means of addressing
inadequate treatment and achieving confidence and esteem for patients’ mental and physical needs
(Pitman et al., 2018). According to Stanton et al. (2018), if a patient has a prior history of mental illness
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or specifically experienced a depressive state, that patient is more likely to experience depression post
cancer diagnosis.
Current Evidence-Based Interventions
The National Comprehensive Cancer Network (NCCN) convened the first Distress Management
(DM) Panel in 1997, producing the first DM Guidelines (NCCN, 2022). The current NCCN DM
Guidelines define distress broadly as “a multifactorial unpleasant experience of a psychological, social,
spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its
physical symptoms, and its treatment” (NCCN, 2022). The NCCN standard for DM includes: 1)
Recognizing, monitoring, documenting, and treating distress promptly at all stages of disease; 2)
Identifying the level and nature of distress; 3) Screening for distress at every medical visit or regular
intervals; and 4) Assessing and managing distress according to clinical practice guidelines. The objective
of systematic DM is not only to identify patients experiencing distress but also to address identified
symptoms and needs by implementing evidence-based interventions with demonstrated efficacy
(Jacobsen, 2009). Educating and familiarizing clinicians to a depressive screening tool and implementing
the correct type of treatment and resources is essential to improving depression in pediatric oncology
patients.
In the ensuing years, more organizations have called attention to the importance of monitoring the
psychosocial well-being of individuals with cancer. In 2007, the National Academies of Science,
Engineering, and Medicine (formerly the Institute of Medicine) advocated routine assessment of the
psychosocial needs of patients with cancer as a standard of care (Page & Adler, 2008). In 2009, the
American Society of Clinical Oncology (ASCO) incorporated the assessment of patients' emotional wellbeing into the Quality Oncology Practice Initiative standards (Neuss et al., 2005). In 2012, the American
College of Surgeons Commission on Cancer (CoC) identified distress screening as an essential part of
quality cancer care (ACOS, CoC, 2012). In 2015, psychosocial distress screening became an accreditation
standard for the CoC, providing the first critical step toward universal adoption of DM practices (CoC,
2015). The CoC accreditation standard includes general requirements regarding timing, methods, and
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tools for screening, follow-up assessment and referral for positive screens, as well as documentation of
screening results.
The American Psychosocial Oncology Society (APOS), the Association of Oncology Social
Workers, and the Oncology Nursing Society issued a joint statement of recommendations for distress
screening in 2014 (Pirl et al., 2014). These recommendations included: Adoption of the NCCN definition
of distress, selection and use of validated screening instruments following published threshold values and
ranges, use of screening instruments that are focused broadly on components of distress (vs one particular
symptom), screening at multiple time points, screening results to be communicated to and reviewed by
the patient's treatment team in a timely manner, follow-up of positive screens by a trained clinician who
can differentiate causes of distress and ensure appropriate referral, and inclusion of referrals for the
assessment and management of distress as part of a patient's routine medical care.
Purpose and Objectives
The purpose of this DNP Project was to evaluate the DanceBlue Clinic’s (DBC) physicians and
Advanced Practice Providers (APPs) knowledge of the Center for Epidemiological Studies Depression
Scale for Children (CES-DC), analyze their clinical practice pertaining to depression in pediatric
oncology patients, and determine if the DBC utilized a DM protocol.
The four aims of this study included:
1. Provide education to Physicians and APPs at the University of Kentucky’s Pediatric DBC
regarding the importance of early recognition of depression among pediatric oncology
patients and the CES-DC via a voiceover educational PowerPoint.
2. To evaluate knowledge of the CES-DC and compare clinical practice of the use of the CESDC, via a pre- and post-educational survey.
3. To determine professional barriers associated with performing depression screening pre- and
post-PowerPoint presentation.
4. To encourage a clinical practice change by standardizing a depression screening tool within
the DanceBlue Oncology Clinic, used with every patient during their treatment.
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Theoretical Model
The theoretical framework that guided this project was the Iowa Model. The model serves as a
pathway to evidence-based practice (EBP) by providing a seven-step process to help identify issues or
knowledge focus triggers, provide quality research solutions, and implement changes (Iowa Model
Collaborative, 2017). The Iowa Model was a good fit for the early recognition of depression protocol
practice change via a standardized depression screening tool because of the emphasis on quality research
and EBP implementing a clinical practice change within a hospital. The concepts adapted from the Iowa
Model for this project include the systematic stepwise approach: identify the problem, conduct research,
and bring light to the most relevant literature, critique the sought-out literature and evidence, and
determine if there is sufficient evidence to create a practice change (Brown, 2014). Depression among
pediatric oncology patients was identified as the problem. The following steps were to implement the
CES-DC as the practice change, monitor the effectiveness of the practice change, then determine if the
practice change could be officially adopted and disseminated into clinical practice. For the overall goal to
implement a standardized depression screening tool as well as to hire a psychologist to the oncology care
team, the primary investigator (PI) needed to evaluate two questions: First, what are the psychological
consequences of depression in pediatric oncology patients? Second, what is the importance of early
recognition and treatment of depression? This framework was used as a guide to build a proper EBP
clinical change regarding early recognition of depression in pediatric oncology patients.
Review of Literature
A literature review was conducted to address the following research question: Do pediatric
oncology patients who are screened and treated for depression early in their treatment, compared to those
pediatric oncology patients who are only screened for depression after showing physical signs of
depression later in their treatment regimen have a better HRQOL? When searching the PUBMED
database, CINAHL database, and PSYCHINFO database, the mesh terms “children” AND “depression”
AND “cancer” AND “CES-DC” AND “screening” AND “oncology” yielded 2,746 articles. Free full text,
human species, and publications within the last 10 years (2010-2020) limited the results to 519. Results
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were limited further, yielding 141 results when applying journal articles and clinical trials. Of those 141
articles, six were chosen to review based on relevance to interventions and depression in pediatric
oncology patients. Through these six articles, ancestry searching was applied, and seven more articles
were inclusive due to the relevance of the subject matter. English, free full text, human species, children
subject, article for the resource type, and peer reviewed concluded to 25 articles that best fit the narrowed
topic (see Table 1).
Synthesis of Evidence
Many cancer patients and survivors suffer from psychological problems, such as depression. The
most common forms of emotional distress are depressive and anxiety disorders that affect about 25% to
35% of this population (DeJong et al., 2006; Hedström et al., 2005; Kunin‐Batson et al., 2016; Sawyer et
al., 2000; Yardeni et al., 2020). Similar rates were found in a previous study demonstrating that in cancer
patients aged 7–21 years 37.4% met the DSM-5 criteria for depressive and/or anxiety disorders (Yardeni
et al., 2020). This may interfere with the patient’s ability to cope with the burden of the illness, and it may
decrease acceptance of treatment, extend hospitalization, reduce quality of life, and increase suicide risk
(D’Souza et al., 2019; Esmaeeli, 2014).
Evidence of depression among pediatric oncology patients (Bamonti et al., 2018; Gordijn et al.,
2012; Mattsson et al., 2019), proves similarities between depressive symptoms and the side effects of
cancer and the associated treatments (Linden et al., 2012). Given that depression increases the risk of
mortality, patient suffering, and healthcare expenditure in pediatric oncology patients (Geue et al., 2018;
Gordijn et al., 2012; Mitchell et al., 2011), it is imperative to recognize depressive symptoms early and
intervene after the initial diagnosis (Bamonti et al., 2018; Cavuşoğlu, 2001; D’Souza et al., 2019; Linden
et al., Lemon et al., 2004; Kalter et al., 2018).
Dismissed depressive symptoms can lead to increased depression scores on the CES-DC
throughout the trajectory of cancer treatment (Bamonti et al., 2018). Therefore, screening patients
immediately after the initial diagnosis and continuation screening, can lead to higher quality of life and
health outcomes (Bamonti et al., 2018; Brintzenhofe-Szoc et al., 2009; Cavuşoğlu, 2001). The following
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months leading up to the one-year mark, post initial diagnosis of cancer, can be the most detrimental time
for pediatric patients regarding depression and quality of life. Considering the high rates of anxiety and
depression among children with cancer, the American College of Surgeons Commission on Cancer, the
Institute of Medicine, the American Cancer Society, and the NCCN require that cancer treatment centers
implement screening programs for psychosocial distress of patients as a new criterion for their clinical
accreditation (Meyers et al., 2014; Lazor et al., 2019).
Two studies (D’Souza et al., 2019; Esmaeeli et al., 2014), examined the coping strategies used
among pediatric oncology patients at various times throughout the first year of treatment. The coping
strategies were based on primary coping (positive reinterpretation, emotional processing, problemfocused coping, and seeking social support), secondary coping (positive thinking, acceptance, cognitive
thinking) and disengagement coping (avoidant-approach, denial, wishful thinking). Both studies found a
significant correlation between disengagement coping and increased depression scores with slower
recovery time than those who practices primary and secondary coping with lower depression scores and
faster recoveries.
Although evidence supports the increased risk of depression among pediatric oncology patients in
comparison to healthy children (Barker et al., 2019; Gordijn et al., 2012; Mitchell at al., 2011), not all
studies support these findings. Peikert et al. (2018) found depression had little to no more significance
amongst oncology patients than it had among healthy children, suggesting that although mood disorders
occur in 30-40% of patients in a hospital setting, clinicians should remain aware of more significant mood
complications other than depression.
Two studies (Barker et al., 2019; Lemon et al., 2004), found that although there is an increased
prevalence rate among pediatric oncology patients; age, gender, and environmental factors have a
significant effect on depression scores. Barker et al. (2019) and Compas et al. (2014), recognized that
children, adolescents, and young adults to have six times higher risk of depression compared to the
general population; however, female gender and other life limiting chronic conditions such as HIV and
thalassemia had greater prevalence of depression than those of males in the oncology population. Lemon
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et al. (2004) found maternal distress to be the number one factor causing increased depression in pediatric
oncology patients 1-6 years of age and 13-17 years of age. It is important to note that although these
studies recognize a correlation between external factors and increased depression scores, they do not
negate the need for early detection with interval screening throughout the first year of treatment as a core
aspect of care and support offered to pediatric oncology patients.
Moreover, early detection and frequent use of a standardized screening tool for depression
provides valuable guidance for anticipatory psychiatric interventions, as those children are more likely to
need extra psycho-oncological support (Barker et al., 2019; Lemon et al., 2004; Gordijn et al., 2012;
Brintzenhofe-Szoc et al., 2009). This is important information to healthcare professionals in the clinical
setting and validates the clinical significance of patient/family centered care. Kalter et al. (2018) suggest
that lower depression levels in pre-school children up to seven years of age is due to the lack of cognitive
awareness and understanding of their illness and the inability to recognize the difference between
themselves and other children.
Identification of Knowledge Gaps
Managing distress in patients with cancer is well documented as an important component of
evidence-based approaches to optimizing cancer outcomes and is a key component of patient centered
cancer care. DM refers to the comprehensive system that includes screening, assessment, triage,
intervention, and outcome monitoring related to patient distress (APP, 2022). The practice of DM
involves proactive use of patient-reported outcomes to identify and triage distressed patients with specific
care needs to appropriate supportive care services for relevant evidence-based intervention. Over 20 years
ago, the NCCN proposed DM to facilitate the delivery of evidence-based psychosocial support services to
patients across the continuum of cancer care: diagnosis, treatment, posttreatment survivorship, advanced
disease, and/or end of life (Deshields et al., 2021).
In recent years, multidisciplinary cancer care teams have developed specific distress screening
tools to effectively and systematically measure distress experienced by patients with cancer. In addition,
clinical researchers have developed and tested novel and effective interventions to promote adherence to
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therapy, enhance shared decision-making, and improve patients' symptom management, quality of life,
and long-term survival (Faller et al., 2013). Despite these advances, many patients do not receive needed
services, which may reflect ineffective screening, such that those with the greatest need are not identified
(Ernstmann et al., 2009).
This gap in care is likely associated with variability in the extent to which DM procedures are
implemented across and within cancer programs and specialty departments. In addition,
professional/institutional responses to positive screens have lacked systematization and utilization of
evidence-based interventions (Deshields et al, 2021). Within the DBC, there was a lack of consistency
and knowledge among the physicians and APPs regarding an existing screening tool as well as a universal
practice/protocol. The inconsistency is not uncommon due to existing guidelines, recommendations, and
accreditation standards for DM lacking detailed implementation guides and consistency (NCCN, 2020;
Carpenter et al., 2022; Blinder et al., 2022). For example, the CoC accreditation standards for patientcentered care generally do not state when, how, or how often to screen and respond to patients'
psychosocial needs (Blinder et al., 2022). As a result, cancer treatment centers across the United States
have implemented DM protocols that vary widely in screening characteristics, including instrumentation,
periodicity of assessments, and procedures for responding to positive screens (Mirosevik, 2019; Zebrack
et al., 2018). This lack of consistency within the United States (and across the world) contributes to
variations observed in clinical practice outcomes related to the implementation of DM protocols and
complicates the interpretation of research results across studies that are geared toward understanding and
better managing this issue (Mirosevik, 2019; Zebrack et al., 2018).
Addressing the Gaps
Standardized depression screening tools are instruments relevant to the treatment of depression.
Initial assessments of depressive symptoms can help determine possible treatment options, and periodic
assessment throughout care can guide treatment and gauge progress (Scaraceno et.al., 2018). Providers
can detect early signs of depression once implementing a standardized screening tool into the continual
intervention treatment plan for pediatric oncology patients, thus beginning treatment for depression
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quickly if warranted. Once they have diagnosed depression, clinicians may use effective psychotherapy
which is shown to reduce distress and suffering, help patients to build effective coping strategies used for
treatment and illness stressors, provide a support system, and help facilitate HRQOL (Vodermaier et al.,
2009).
The incorporation of DM protocols such as implementing a standardized screening tool, can aid
cancer centers to bridge the gap from screening to provision of evidence-based psychosocial oncology
care. Adherence to DM protocols in cancer care can improve patients' quality of life, reduce distress,
reduce anxiety and depression, achieve medical cost offsets, reduce emergency department visits and
hospitalizations, and is associated with improved survival through biobehavioral mechanisms (Faller et
al., 2013; Schneider et al., 2010; Carlson et al., 2010; Duarte et al., 2015; Zebrack et al, 2017; Lutgendorf
et al., 2015).
The frequency of screening represents another point of variability in screening practice. The
NCCN guidelines have specified the aspirational goal of screening every patient/every visit as a
component of patient-centered care, but many institutions struggle with the logistics and resources
associated with screening at every visit (NCCN, 2019). CoC guidelines specify that patients should be
screened once during their first course of treatment (ASCO, 2020; Deshields et al., 2021). The latest
Quality Oncology Practice Initiative Certification Program Standards (Standard 1.4) require screening and
intervention with each cycle of chemotherapy (Zebrack et al., 2018).
Methods
Design
The DNP project was a prospective, single-arm, pre- and post-design to test the effectiveness of
an educational intervention on the knowledge and use of a standardized depression screening tool.
Setting
This DNP project was performed at the University of Kentucky Children’s Hospital in Lexington,
Kentucky (UKCH). UKCH is a designated Magnet, academic medical center in the United States. The
DanceBlue Kentucky Children’s Hospital Hematology/Oncology Clinic within UKCH is a designated
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cancer center that offers comprehensive pediatric hematology and oncology services provided by a
multidisciplinary team of experts.
Project Congruence
A priority in this project was to align with the philosophy and innovation value in UK Children’s
Hospital values: Diversity, Innovation, Respect, Compassion, and Teamwork. The Innovation value
embraces continual learning and improvement to drive positive change and outcomes. This study had no
effect on employment of performance evaluations for DBC physicians and APPs, nor an allotted budget.
Stakeholders
Stakeholders within the Doctor of Nursing Practice committee consisted of chair member, Dr.
Misty Ellis, clinical mentor, Caryn Sorge, MD, and faculty mentor, Dr. Andrew Makowski. Additionally,
in support of this study was Chief of the Division of Hematology/Oncology Department of Pediatrics,
John D’Orazio, MD, PhD, and Research Protocol Manager, Tammy Taylor, RN, MSN. Other University
of Kentucky stakeholders consisted of the oncology treatment team for their time and commitment,
administrators’ buy in, along with data and statistical analysis support from Dr. Amanda ThaxtonWiggins.
Sample
A convenience sample was recruited through the DBC identifying APPs and Attending
Physicians employed at the DBC. Inclusion criteria included: a.) Physician and APP b.) Employee of
DanceBlue Kentucky Children's Hospital Hematology/Oncology Clinic. Exclusion criteria included a.)
Medical professionals other than physician or APP, b.) Medical students and APP students, c.) Physician
or APP from a different unit other than DBC and 4W, d.) Pediatric patients without an
oncological/Hematological diagnosis, e.) Pediatric patients under the age of five and over 21, f.) Pediatric
patients not being treated by the DBC Treatment Team.
Procedure
Approval for this study was granted from the Institutional Review Board (IRB) affiliated with the
University of Kentucky Medical Center IRB. Approval was also granted by the Chief of the Division of
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Hematology/Oncology Department of Pediatrics through the facility’s Research Protocol Manager.
Physicians and APPs were then contacted via their @uky.edu e-mail containing the informed consent
cover letter and an electronic invite to participate in the linked study (see Appendix 1). The following
steps were completed to successfully analyze the study’s intervention: a.) Qualtrics pre-survey (see
Appendix 2), b.) An educational voiceover PowerPoint containing information from EBP literature on
depression, early recognition of depression, standardized depression scales, and the CES-DC (see
Appendix 4), c.) Two weeks past the initial invite to the electronic pre-survey, the PI sent out an
additional e-mail inviting DBC physicians and APPs to participate in the post-educational survey, only
for those who participated in the pre-survey and educational PowerPoint, via their @uky.edu e-mail (see
Appendix 3)
Measure/Instruments
The style of questions on the pre- and post-survey included multiple choice, select all that apply,
and free form. Non-identifying demographic information was collected in both the pre- and post-surveys
including a.) Professional role, b.) Number of patients cared for in a day, and c.) Age range of patients
cared for in day. Participants were also asked on both the pre- and post-survey if they 1.) Had knowledge
of a depression protocol and screening tool within the clinic, 2.) If it was in their clinical practice to use a
depression screening tool, 3.) Knowledge of barriers to screening patients, 4.) Knowledge of the CES-DC,
and 5.) Knowledge of gaps related to depression in the pediatric oncology patient population.
In both the pre- and post-surveys, participants were asked to answer, “When a patient is
presenting with depressive symptoms do you…select all that apply” with the following options: a.)Refer
to the licensed social worker, b.) Refer to child life, c.) Refer to Oncologist, d.) Refer to APP, e.) Refer to
child psychologist, f.) Perform a depressive screening tool, g.) Treat patient for depression with
medication, h.) Talk with patient about signs/symptoms and recommend outlets for stress and
feelings/thoughts, and/or i.) Assume it is related to their cancer diagnosis and reassure patient it is
common, but do not diagnose depression or treat depression.
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The educational PowerPoint topics included: The definition and background information on
depression, risk factors, importance of screening early, standardizing a depression screening tool, the
innerworkings of the CES-DC (see Appendix 4), and the advantages of the use of the CES-DC.
Following the educational PowerPoint, the post-survey assessed the likelihood of using the CESDC in clinical practice by asking if there was a clinical practice change made regarding depression. The
post-survey also asked the participants if they encountered any barriers when implementing the CES-DC
and if they observed any knowledge gaps once learning about the CES-DC (see Table 3 and 4). For future
research replication purposes, participants were asked their opinion on the educational PowerPoint and if
they would choose to implement the CES-DC in clinical practice.
Data Collection
Participants were provided a unique link by email to access the surveys, participate in the study,
and to preserve anonymity. Qualtrics was used to collect data, for which UK has a license. The first
question on the pre- and post-survey contained an anonymous one-question identifier limited to a color
and a set of four-digit numbers (ex: GREEN-1055). This unique identifier allowed for pairing pre- and
post-intervention surveys. No identifiable data were obtained nor reported in this study.
Data Analysis
Statistical analysis was performed using IBM SPSS, version 26. Descriptive analysis was used to
summarize participant characteristics. Changes in pre- and post-survey items were analyzed using
McNemar’s test. An alpha level of .05 was used to determine statistical significance.
Results
Demographics
A total of twelve professionals were invited to participate in the study over a period of two
months. Eight were enrolled (67% response rate), and eight participants completed the pre- and postsurvey. Among respondents, 50% were Physicians and 50% were APPs (see Table 2). The majority of
participants reported treating five to ten patients in one day (87.5%), while fewer reported treating 10-15
patients in a day (12.5%). Of those patients seen in a day, half reported zero to four patients between the
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ages of 5-21 years, and the other half were treating five to ten patients in a day between the ages of 5-21
years.
Findings
When comparing the pre- and post-survey responses, there was no statistically significant
improvement in the number of patients screened in the clinic between the ages of 5-21 for depression (see
Table 4). The pre-survey percentage of participants that did not screen every patient in the clinic 5-21
years of age was 87.5% (n=7), and the post-survey score was 87.5% (n=7). The increase in the number of
participants that attempted to screen more patients, but not every patient on the post-survey improved by
half (n=4). Participants (12.5%) subjectively reported that, “Every child diagnosed with cancer should
immediately have a referral to a child psychologist who can work collaboratively with that team
throughout each patient's treatment course.” Additional subjective data reported by 12.5% of participants
(n=1) stated, “Would love to see us develop a more standardized approach to depression screening, but it
needs to have a small footprint that doesn't interfere with provider efficiency.”
There was no statistically significant improvement in the belief that there is a gap in recognizing
early signs/symptoms of depression in pediatric oncology patients (p=.50). The pre-survey response was
87.5% (n=7) and the post survey response was 62.5% (n=5). Among the participants who believed there
was a gap in treating depression in pediatric oncology patients on the pre-survey (n=7), only 62.5% (n=5)
believed there was a gap on the post-survey, thus indicating there was no statistically significant
improvement in recognizing the gap in treating depression in pediatric oncology patients (p=.50; see
Table 4).
When comparing the pre- and post-survey, it was within 37.5% of participants practice to treat
patients for depression without performing a depressive screening tool on the pre-survey (n=3), and 0.0%
on the post-survey (p-value for McNemar’s test is not estimable since all responded no on the posteducation survey). It was reported on the pre-survey that 62.5% (n=5) would refer to a Social Worker,
12.5 (n=1) refer to a child Psychologist, 25.0% (n=2) would treat with medication, and 25.0% (n=2)
would also talk about signs/symptoms and recommend safe outlets/resources (see Table 2). On the post-
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survey, there was more of a universal answer among the eight participants with 62.5% referring to a
Social Worker (n=5) and 37.5% would talk about signs/symptoms and recommend safe outlets/resources
(n=3; see Table 3).
Of the physicians and APPs that participated in the pre-survey (n=8), three-quarters reported
barriers to screening every patient between the ages of 5-21 years of age (75.0%). One participant
(12.5%) subjectively reported “Clinical focus is often on acute measures to sustain life, while screening
for psychosocial issues can become secondary.” Additionally stated by 12.5% of participants (n=1),
“Barriers to screening are time and lack of expertise. Most of us feel comfortable identifying when a child
is struggling with depression and starting initial therapy. If there are other complications/multiple
medications or if there is something not straightforward about it then we usually consult psych to get
involved.”
Among the participants (n=8) who provided data in the post-survey after reviewing the
educational PowerPoint, only 37.5% attempted to use the CES-DC (n=3), and three-quarters
recommended screening every patient in the clinic and oncology patient admission to 4W (75%; n=6).
Additionally, 87.5% of participants recommended the CES-DC on the post-survey (n=7), and 75% (n=6)
were willing to make the practice change (See Table 3).
On the post-survey, 62.5% of participants (n=5) subjectively reported in the questions, concerns,
and comments box. 12.5% (n=1) of participants asked, “Could this form be built into Epic? Is it available
in multiple languages?” 12.5% of participants (n=1) stated, “Every oncology patient should have
screening at every visit. I would like to see our clinic standardize the way we screen patients. Thank you
for your very informative presentation.” 12.5% (n=1) of participants stated, “MD doesn't have time to do
depression screen. also feel like having a patient fill out a depression screening tool every single time we
interact with them is a little over kill.” 12.5% (n=1) of participants reported, “My clinical practice is to
ask about emotional concerns during my ROS when I admit or see patients in clinic. If there is a concern,
I continue discussions and immediately refer to our LCSWS. I believe that a standard tool would be
useful when considering starting and evaluating effectiveness of antidepressants.”
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Discussion
The intentions of this DNP project were to promote early recognition of depression in pediatric
oncology patients who seek care in the DBC, as well as compare physician and APP clinical practice
regarding depression before and after reviewing an educational PowerPoint on the CES-DC. A primary
aim of this study was to identify professional barriers associated with performing depression screening
pre- and post-the PowerPoint presentation. Evidence from this DNP project shows there is not a DM
protocol in the DBC regarding screening methods for depression. Patients are treated for depression by
physician and APP preference. This is likely due to existing guidelines, recommendations, and
accreditation standards for DM not meeting consistent detailed implementation guides (Deshields et al.,
2021). This lack of consistency within the United States contributes to variations observed in clinical
practice outcomes related to the implementation of DM protocols and complicates the interpretation of
research results across studies that are geared toward understanding and better managing this issue
(Zebrack et al., 2016; Zebrack et al., 2018).
In comparing pre- and post-survey variables there was no difference in screening intentions
(frequencies were the exact same), therefore the intentions to treat for depression without using a
screening tool cannot be analyzed because all said, “no” in the post-survey. A second aim of the study
was to provide a PowerPoint to physicians and APPs with enough education to highlight the need for the
use of a standardized depression screening tool by making a clinical practice change. However, it was
difficult to analyze future intentions of a clinical practice change using a screening tool, because although
37.5% (n=3) of participants felt their clinical practice was effective in recognizing and treating
depression, a majority of participants chose not to screen every patient seen in the clinic or on 4-West
between the ages of 5-21 for depression after reviewing the educational PowerPoint (87.5%).
The qualitative data suggest the need for the implementation of a DM protocol within the DBC to
utilize a standardized depression screening tool represented by several participants stating they did not
have time to screen every patient. Evidence within the literature suggests HRQOL is linked to disease
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progression, therefore the task of not only screening pediatric oncology patients, but every patient, needs
to be assigned to a professional in the clinic with designated time.
While evaluating the quantitative data in the post-survey responses, it is evident that all eight
providers found the educational PowerPoint informative. The implementation of the CES-DC used on
every patient visit in the DBC and 4 west unit (4W) admission provides a universal distress management
protocol among the APPs and Physicians and closes the knowledge gap on clinical practice and the
specific type of screening tool used. Educating providers about the CES-DC and the importance of a DM
protocol specific to the pediatric oncology population not only expands the knowledge of the physicians
and APPs, but it also emphasizes the need for a clinical practice change to improve patient care and
HRQOL among pediatric oncology patients.
Implications for Practice, Education, Policy and Research
This study has highlighted several implications for future research. With the small sample size
represented in this study, future research could focus on a larger sample including oncology treatment
teams in the surrounding area i.e., Norton’s Children’s Hospital and Cincinnati Children's Hospital
Medical Center. More pointed questions should be added into the pre- and post-survey including 1.)
Years of practice, 2.) Screening confidence (on a five-point Likert scale), 3.) Type of education received
for mental health of oncology patients, 4.) Number of patients diagnosed with depression, 5.) Number of
patients prescribed antidepressants including SSRIs, benzodiazepines, and psychotropics, 6.) Number of
patients referred to the licensed social workers for suspected depression, 7.) Interest in bringing on a
licensed psychologist to the treatment team (on a five-point Likert scale), 8.) Total scores of those patients
screened with the CES-DC, 9.) Barriers to screening patients with a comment box provided. Specifically
pertaining to the DBC, future researchers should invite the licensed social workers to participate in this
study with the modified pre- and post-survey questions.
More research needs to be completed in comparing various standardized depression screening
tools to use among the pediatric oncology patients for validity and consistency. Found within the
literature, Compas et al. (2014) measured the validity, consistency, and specificity of the Psychosocial

23

Screen for Cancer (PSSCAN) created specifically for oncology patients. The PSSCAN is used in the
DSM-IV as a 21-item questionnaire on a five-point Likert scale to assess anxiety, depression, and quality
of life. However, this was the only article found using the PSSCAN screening tool and the article’s
sample consisted of adults.
Further investigation is needed to gather data regarding specific standardized screening tools best
utilized for educating providers, as well as how to implement the educational PowerPoint into a webbased training (WBT) for future providers joining the oncology treatment team. Once the specific
screening tool is decided upon and the WBT is created, future research can develop a comprehensive DM
protocol for the use of a standardized depression screening tool and implement the practice change into
the facility for a new study. It would also be useful to investigate the precedent set at other healthcare
institutions and evaluate their standardized policy and protocol for pediatric oncology patients presenting
with signs/symptoms of depression. “Cancer for the Whole Patient” was published by the Institute of
Medicine in 2008, providing a clear and strong recommendation that the provision of psychosocial
services be adopted as a standard of quality cancer care set forth by the American College of Surgeons
(ACoS) and the CoC. Key findings from this study indicated that the psychosocial health care needs of
patients with cancer are not being adequately addressed despite evidence supporting the effectiveness of a
range of services to help patients and their families manage the psychosocial aspects of cancer.
Beginning in 2015 a new standard of care was set in place by the ACoS and the CoC, requiring
cancer centers to implement screening programs for psychosocial distress as a new criterion for
accreditation (Pirl et al., 2015). The ACoS, CoC, Association of Oncology Social Work (AOSW), and
Oncology Nursing Society (ONS) endorsed the new CoC standard 3.2 on psychosocial distress screening
recognizing that it will help address unmet psychosocial needs and improve “cancer care for the whole
patient” (Pirl et al., 2015). According to Standard 3.2: Psychosocial Distress Screening, each center must
have a cancer committee that “develops and implements a process to integrate and monitor on-site
distress screening and referral for the provision of psychosocial care. This standard addresses issues
related to the time of screening, screening tools and methods, assessment and referral, and documentation.
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Nursing staff are at the front lines of patient care and their thoughts should be evaluated as well.
Nursing could be incorporated into the DM protocol if hiring a licensed Psychologist, trained in psychooncology, onto the oncology treatment team is not feasible. Screening consistency within the DBC and
the implementation of a developed DM protocol would be feasible if a psycho-oncology cancer
committee is formed.
As a community of healthcare providers, it is our goal to reduce the rate of depression and
improve quality of life. Evidence suggests integrating multidisciplinary depression interventions into
cancer care as a cost-effective means of addressing inadequate treatment and achieving confidence and
esteem for patients’ mental and physical needs (Pitman et al., 2018). It is apparent within this study’s data
that there is a lack of psycho-oncological initiative within the DBC. There is not one preferred screening
tool over the other, nor is there a developed DM protocol. Therefore, each patient is treated differently
based on the education and clinical practice of the provider. DBC patients would have a universal
treatment plan that meets the standards of an accredited cancer care center if Standard 3.2 of the ACoS
and CoC were met. Moreover, the data from this study amplifies the need for an individual(s) that have
the time for educational training and implementation, based on personal comments about the lack of time
for screening in the pre- and post-surveys.
Limitations
Several limitations were identified in the design of this study. Choosing one unit to implement the
study created a limitation due to the small existing sample size of 12 physicians and APPs in total making
up the pediatric oncology treatment team. Of the 12 physicians and APPs invited to the study, only eight
participated thus creating a smaller sample size. The success and accuracy were highly dependent on the
time and willingness of the providers as well as their two-week follow through with the post-survey.
Therefore, lack of time, patience, and dedication to the study could have fallen through from the
beginning of the study to the end.
COVID-19 created several limitations regarding face-to-face, interactive education and project
discussion on a personal level leaving technology as the only line of communication. Virtual technology
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was available to contact providers for reminders of deadlines, but those deadlines were still missed
causing the study deadline to be pushed back. This was likely due to summer vacations, patient load, and
other work/personal priorities.
While there was little research to be found on the accuracy of the CES-DC, there was a large
quantity of research to be found using the CES-DC to diagnose depression among pediatric oncology
patients. Therefore, the search was narrowed to those studies utilizing the CES-DC as opposed to how
accurate it is. However, there was no limit to the number of articles provided on depression amongst
pediatric patients and the long-term effects they endure.
The length of time designated to complete the study posed an additional limitation. To keep the
project manageable and ensure that it met the target deadline, the time of the project was minimized to
one month in total. Had the two weeks been extended to a month or even two months to implement the
CES-DC into providers’ practice, there would potentially be more feedback and willingness to pilot the
temporary practice change.
Conclusion
The data results from this study found that there was not an implemented DM protocol, nor a
universal standardized depression screening tool used among the Physicians and APPs in the DBC. Each
patient is screened and treated for depression differently than the next patient based upon the Physician’s
and APP’s personal clinical practice. There were few barriers found when screening patients, however the
two primary barriers were lack of time among the clinical professionals and screening consistency.
Opportunity exists to better utilize the tools set in place by the ACoS and CoC to develop a DM protocol
to apply a standardized depression screening tool by the psycho-oncological committee to every DBC
patient. It is recommended that this project be replicated with a larger sample size, additional survey
questions regarding the CES-DC patient scores, and the idea of a licensed psychologist hired on to the
pediatric oncology treatment team to improve pediatric oncology patients’ HRQOL and screening
consistency.
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Table 1. Evidence Table

Study
Author
Bamonti, P. M.,
Moye, J., &
Naik, A. D.

Year

2018

Number of
Participants
122

Sample
Characteristic
Treatment
Length: 118mo/MA:65

Study Design

Intervention

Major
Finding

COHORT,
CASE
CONTROL

DSM-IV & PHQ-9
Intervals

Increased
Depression

Increased
Depression

Barker MM,
Beresford B,
Bland M, Fraser
LK

2019

6,042

5-25 years of
age

SR, META
ANALYSIS OF
RCTs

HADS, CDI, DSMIV, DIKJ, SELFREPORT/PARENTREPORT -Different
tools used in different
locations at time of
diagnosis)

BrintzenhofeSzoc, K. M.,
Levin, T. T., Li,
Y., Kissane, D.
W., & Zabora, J.
R.

2009

8,265

MA: 54 years
of age

COHORT,
CASE
CONTROL

BSI, SCL-90, HADS,
HAM-D

Increased
Depression

Cavuşoğlu, H.

2001

100

9-13 years of
age

QUASI-EXP,
NON-RANDOM
CT

CES-DC- compared
cancer vs healthy
children

Increased
Depression

COHORT,
CASE
CONTROL

RSQ-PC, CBCL, YSR
CHILD SELF
REPORT, PARENT
SELF REPORT of
children’s coping at
interval times.

Increased
Depression

SR, METAANALYSIS

Compared cancer
patients in first year of
treatment to healthy
children.

No effect

SINGLE
QUALITATIVE,
DESCRIPTIVE,
QI

CES-DC screened;
8±5.3 days of hospital
stay. Compared
children with chronic
renal disease,
malignancy, and acute
disease
CES-DC , PHQ-9,
GAD-7; Cancer pts
diagnosed <5 years,
Screened 1yr and
lifetime.

Compas, B. E.,
Desjardins, L.,
Vannatta, K.,
Young-Saleme,
T., Rodriguez,
E. M., Dunn,
M., & Gerhardt,
C. A.
D’Souza, A. M.,
Devine, K. A.,
Reiter, P. J.,
Gerhardt, C. A.,
Vannatta, K.,
Noll, R. B., &
Reiter-Purtill, J

Esmaeeli MR,
Erfani Sayar R,
Saghebi A

Geue, K.,
Brähler, E.,
Faller, H.,
Härter, M.,
Schulz, H.,
Weis, J., … &
Mehnert, A.
Gordijn MS, van
Litsenburg RR,
Gemke RJ
Linden, W.,
Vodermaier, A.,
MacKenzie, R.,
& Greig, D

2014

2019

2014

2018

2012

2012

635

117

90

5-17 years of
age

18 years of age

8-16 years of
age

302

15-39 years of
age

COHORT,
CASE
CONTROL

62

5-15 years of
age

SR, METAANALYSIS

CHQ, CDI- Screened
22–62 months after
finishing treatment

10,153

MA: 59 years
of age

SR, METAANALYSIS

DSM-IV-Screened
patients after diagnosis
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Increased
Depression

Increased
Depression

Increased
Depression

Increased
Depression

Mattsson, S.,
Olsson, E.,
Carlsson, M., &
Johansson, B
Myers, R. M.,
Balsamo, L., Lu,
X., Devidas, M.,
Hunger, S. P.,
Carroll, W. L.,
& Kadan‐
Lottick, N. S
Ruland, C. M.,
Hamilton, G. A.,
& SchjødtOsmo, B
Satin, J. R.,
Linden, W., &
Phillips, M. J.
Zeltzer, L. K.,
Recklitis, C.,
Buchbinder, D.,
Zebrack, B.,
Casillas, J.,
Tsao, J. C., Lu,
Q., & Krull, K.

2019

558

UTBD-

COHORT, CASE
CONTROL

eVAS, HADS, STAIS, MADRS-Sl
screened cancer
patients <6mo
diagnosed, compared
the length and validity
of all.

Increased
Depression;
High
Validity

Increased
Depression

2014

159

2-9 years of
age

SR, METAANALYSIS

(SR-ALL) during the
first year of therapy
and identified
associated risk factors,
1, 6 and 12 months
after diagnosis.

2009

5,059

7-12 years of
age

SR, META
ANALYSIS OF
RCTs

SISOM- self report

Increased
Depression

MA: 47.8

SR, METAANALYSIS

HADS, DSMIII/DSM-IIIR, effects
of depression on
cancer progression

No Effect

SR, METAANALYSIS

BSM-18, HRQOL,
CCSS-NCQcompared cancer
survivors’ quality of
life post treatment to
healthy

2009

2009-2016

2097

7,147

3-15 years of
age

36

Increased
Depression
Decreased
HRQOL.

Table 2. Descriptive summary of participants characteristics (n=8)
n (%)
Professional role
MD
APRN
Patients seen in one day
5-10
10-15
Patients between 5-21years old
0-4
5-10
Knowledge of depressive screening tool used in Clinic
Yes
I don’t know
No
Preferred depressive screening tool
No
Missing respondent
Screen every patient in clinic 5-21 years old
Yes
No
Barriers to screening patients 5-21 years old
Yes
No
Missing respondent
Familiar with the CES-DC
Yes
No
Clinical practice when patient presents with depression signs/symptoms
Refer to licensed Social Worker
Refer to child Psychologist
Treat with medication
Talk about s/sx and recommend safe outlets/resources
Key: s/sx: Signs/Symptoms
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4 (50.0%)
4 (50.0%)
7 (87.5%)
1 (12.5%)
4 (50.0%)
4 (50.0%)
1 (12.5%)
4 (50.0%)
3 (37.5%)
7 (87.5%)
1 (12.5%)
1 (12.5%)
7 (87.5%)
6 (75.0%)
1 (12.5%)
1 (12.5%)
3 (37.5%)
5 (62.5%)
5 (62.5%)
1 (12.5%)
2 (25.0%)
2 (25.0%)

Table 3. Post-survey descriptive summary of intervention (n=8)
n (%)
Attempt to use CES-DC screening tool since the intervention
Yes
No
Clinical practice when patient presents with depression signs/symptoms
Refer to licensed Social Worker
Talk about s/sx and recommend safe outlets/resources
Made a clinical practice change
Yes, I screened every patient
Yes, I tried the CES-DC, but not on every patient
No
Recommend screening every patient
Yes
No
Recommend the CES-DC
Yes
No
Willing to make a practice change
Yes
No
It is already within my practice to screen every patient
Found Educational PowerPoint informative
Yes
No
Key: s/sx: Signs/Symptoms
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3 (37.5%)
5 (62.5%)
5 (62.5%)
3 (37.5%)
1 (12.5%)
4 (50.0%)
3 (37.5%)
6 (75.0%)
2 (25.0%)
7 (87.5%)
1 (12.5%)
6 (75.0%)
1 (12.5%)
1 (12.5%)
8 (100.0%)
0 (0.0%)

Table 4. Changes in outcomes before and after the educational intervention (n=8)
Pre-education
% yes

Post-education
% yes

p

Screen every patient you see in the clinic between
the ages of 5-21 for depression
12.5%
12.5%
-Do you believe there is a gap in recognizing early
signs/symptoms of depression in pediatric
87.5%
62.5%
.50
oncology patients
Do you believe there is a gap in treating of
depression in pediatric oncology patients
87.5%
62.5%
.50
Do you treat children for depression without
performing a depressive screening tool
37.5%
0.0%
n/a*
questionnaire
*Note: p-value for McNemar’s test is not estimable since all responded no on the post-education.
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Appendices
Appendix 1. Informed Consent
Promotion of Early Recognition of Depression in Pediatric Oncology Patients
Survey Cover Letter
Dear UK HealthCare DanceBlue Clinic Oncologist, Hematologist, and APRN:
Researchers at the University of Kentucky are inviting you to take part in a survey study about
depression in pediatric oncology patients. The study is titled” Early Recognition of Depression in
Pediatric Oncology Patients 5-18 Years of Age.” The purpose of this study is to 1. Determine if an
educational voice-over PowerPoint presentation is effective in improving clinical practice; 2. To
determine professional barriers associated with performing depression screening by the healthcare
Pediatric Oncology team pre- and post- an educational voice over PowerPoint presentation; and 3. To
bring awareness of the importance in early recognition of depression in pediatric oncology patients. You
are being invited to participate in this study because you are either an Oncologist, Hematologist, or
APRN, at UK HealthCare Dance Blue Clinic.
Although you may not get personal benefit from taking part in this research study, your
responses may help us understand more about how educational reviews can be used for targeted
barriers regarding clinical practice. Additionally, your responses may have impact on future sought out
evidence based clinical practice for the enhancement of patient care. Some volunteers
experience satisfaction from knowing they have contributed to research that may possibly benefit
others in the future.
Participation is entirely voluntary, anonymous, and confidential. You may withdraw at any time
from participation should you choose. Participation in the study is at no cost to you except for the time
taken to complete the survey. If you do not want to be in the study, there are no other choices except not
to take part in the study.
Your participation will involve answering survey questions about clinical practice regarding
depression. There are two surveys, one to take before listening and reviewing the voice over PowerPoint
presentation and one to take after listening and reviewing the voice over PowerPoint presentation; each
will take about 10-15 minutes to complete. The risks involved in the surveys are minimal. There is
potential for breach of confidentiality, however, this is lessened as the surveys do not collect any
information that is likely to identify any one individual. In no way will participation in this study have
effect on your performance evaluation or job duties. Your responses to the surveys will be kept
confidential to the extent allowed by law. Your response to the survey is anonymous which means no
names, IP addresses, email addresses, or any other identifiable information will be collected with the
survey responses. Researchers will not know which responses are yours if you choose to participate.
When researchers write about the study you will not be identified. The information may be used for future
research or shared with other researchers without your additional informed consent.
Researchers hope to receive completed surveys from approximately 15 people, so your answers
are important to the success of the research study. Of course, you have a choice about whether to
complete the surveys, but if you do participate, you are free to skip any questions or discontinue at any
time. You will not be penalized in any way for skipping or discontinuing the survey. Note, that by
proceeding to the survey link, you are agreeing to participate in the research study.
Please be aware, while we make every effort to safeguard your data once received from the online
survey company, UKY Qualtrics, given the nature of online surveys, as with anything involving the
Internet, researchers can never guarantee the confidentiality of the data while still on the survey
company’s servers, or while in route to the researchers of this study. It is also possible the raw data
collected for research purposes will be used for marketing or reporting purposes by the survey/data
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gathering company after the research is concluded, depending on the company’s Terms of Service and
Privacy policies.
If you have questions about the study, please feel free to ask; contact information is provided
below. If you have complaints, suggestions, or questions about your rights as a research volunteer,
contact the staff in the University of Kentucky Office of Research Integrity at 859-257-9428 or toll-free at
1-866-400-9428.
Thank you in advance for your assistance with this important project. You will find the survey
link attached below.
Survey link: https://uky.az1.qualtrics.com/jfe/form/SV_6qY9h6HrERjB5FI

Sincerely,
Jennifer Blankenship, RN, BSN
Graduate College of Nursing, Student Doctor of Nursing Practice
University of Kentucky
PHONE: 573-268-5552
E-MAIL: jen.blankenship@uky.edu
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Appendix 2. Pre-Survey
Depression in Pediatric Oncology Patients-- Pre-Education Survey

Start of Block: Default Question Block
Q1 Please create a unique identifier that contains a color followed by a set of 4 digit numbers (Example: GREEN1055). This is to compare your pre- and post- survey answers while keeping your identity anonymous. Note: Do not
forget your unique identifier as it will be asked of you again on the post- survey.
________________________________________________________________
Q2 What is your professional role in the Dance Blue Clinic?

o

Pediatric Oncologist, MD (1)

o

APRN (2)

Q3 On average, how many patients do you see in one day?

o

0-4 (1)

o

5-10 (2)

o

10-15 (3)

o

15-20 (4)

Q4 Of those patients, how many on average are between the ages of 5-21?

o

0-4 (1)

o

5-10 (2)

o

10-15 (3)

o

15-20 (4)

Q5 Is there a standardized depressive screening tool used for patients in the clinic?

o

No (1)

o

I don't know (2)

o

Yes (3)

Q6 If you marked yes, do you feel the standardized screening tool is effective?

o

No (1)

o

Yes (2)

o

I marked "I don't know" (3)
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Q7 If there is not a standardized screening tool, or you marked "I don't know", do you use a particular screening tool
you prefer?

o

No (1)

o

Yes (2)

Q8 Do you screen every patient you see in the clinic between the ages of 5-21 for depression?

o

No (1)

o

Yes (2)

o

Yes, but a different age group (3)

Q9 Are there barriers to screening pediatric oncology patients between the ages of 5-21?
▢ No (7)
▢ Yes (8) ________________________________________________
Q10 Do you treat children for depression without performing a depressive screening tool questionnaire?

o

No (1)

o

Yes (2)

Q11 When a patient is presenting with depressive symptoms do you... (select all that apply)

o

Refer to the licensed social worker (1)

o

Refer to child life (2)

o

Refer to Oncologist (3)

o

Refer to APRN (4)

o

Refer to child Psychologist (5)

o

Perform a depressive screening tool (6)

o

Treat patient for depression with medication (7)

o

Talk with patient about signs/symptoms and recommend outlets for stress and feelings/thoughts (8)

o

Assume it is related to their cancer diagnosis and reassure patient it is common, but do not
diagnose depression or treat depression. (9)

Q12 Are you familiar with the Center for Epidemiological Studies Depression Scale for Children (CES-DC)?

o

No (1)

o

Yes (2)

Q13 Do you believe there is a gap in recognizing early signs/symptoms of depression in pediatric oncology
patients?

o

No (1)

o

Yes (2)
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Q14 Do you believe there is a gap in treating early or late signs/symptoms of depression in pediatric oncology
patients?

o

No (1)

o

Yes (2)

Q15 Please write any comments or questions you may have below.
________________________________________________________________

End of Block: Default Question Block
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Appendix 3. Post-survey
Depression in Pediatric Oncology Patients -- Post-Education Survey
Start of Block: Default Question Block
Q1 Please enter your unique identifier that contains a color followed by a set of 4-digit numbers
(Example: GREEN-1055). This will be the same unique identifier you enter on the pre- education survey.
This is to compare your pre- and post- survey answers while keeping your identity anonymous.
________________________________________________________________
Q2 On average, how many patients do you see in one day?
o

0-4 (1)

o

5-10 (2)

o

10-15 (3)

o

15-20 (4)

Q3 Of those patients, how many on average are between the ages of 5-21?
o

0-4 (1)

o

5-10 (2)

o

10-15 (3)

o

15-20 (4)

Q4 Is there a standardized depressive screening tool used for patients in the clinic?
o

No (1)

o

I don't know (2)

o

Yes (3)

Q5 If you marked yes, do you feel the standardized screening tool is effective?
o

No (1)

o

Yes (2)

o

I marked "I don't know" (3)
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Q6 After reviewing the educational power point on the CES-DC, would you change anything about the
Dance Blue Clinic's standardized screening tool?
o

Fewer questions (1)

o

More questions (3)

o

More child friendly (2)

o

I feel it is unnecessary (4)

o

I would change the type of screening tool used (7)

o

Nothing (5)

o

Other (6)

Q7 After reviewing the educational PowerPoint did you screen every patient you saw in the clinic or on 4west between the ages of 5-21 for depression?
o

No (1)

o

Yes (2)

Q8 After reviewing the educational PowerPoint did you attempt to use the CES-DC screening tool?
o

No (1)

o

Yes (2)

Q9 After reviewing the educational PowerPoint did you treat your patients for depression without
performing a depressive screening tool questionnaire?
o

No (1)

o

Yes (2)

Q10 After reviewing the educational powerpoint, when a patient presented with depressive symptoms in
the clinic or on 4-west did you... (select all that apply)
o

Refer to the licensed social worker (1)

o

Refer to child life (2)

o

Refer to Oncologist (3)

o

Refer to APRN (4)

o

Refer to child Psychologist (5)

o

Perform a depressive screening tool (6)

o

Treat patient for depression with medication (7)

o

Talk with patient about signs/symptoms and recommend outlets for stress/feelings/thoughts (8)

o Assume it is related to their cancer diagnosis and reassure patient it is common, but did not
diagnose depression or treat depression. (9)
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Q11 Did you find the PowerPoint presentation informative?
o

No (3)

o

Yes (4)

Q12 Did you make a clinical practice change after reviewing the educational PowerPoint?
o

No, I feel my clinical practice is effective in recognizing and treating depression (1)

o

Yes, I screened every new admission to the clinic, 4-west, or a patient showing signs/symptoms
of depression with the standardized clinic screening tool/screening tool of my choice. (2)

o

Yes, I tried the CES-DC on my patients, but not all (3)

o

Yes, I screened every new admission to the clinic, 4-west, or a patient showing signs/symptoms
of depression with the CES-DC. (4)

Q13 Do you believe there is a gap in recognizing early signs/symptoms of depression in pediatric
oncology patients?
o

No (1)

o

Yes (2)

Q14 Do you believe there is a gap in treating early or late signs/symptoms of depression in pediatric
oncology patients?
o

No (1)

o

Yes (2)

Q15 Would you recommend screening pediatric oncology patients upon every admission, clinic visit, and
a patient showing signs/symptoms of depression?
o

No (1)

o

Yes (2)

Q16 Would you recommend the CES-DC?
o

No (1)

o

Yes (2)

Q17 Would you recommend a specific depression screening tool that you find effective?
________________________________________________________________
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Q18 Would you be willing to make a practice change to screen every patient upon every admission, clinic
visit, and a patient showing signs/symptoms of depression if you have not already?
o

No (1)

o

Yes (2)

o

I made the clinical practice change after reviewing the educational powerpoint (3)

o

It is already in my clinical practice to screen every patient upon every admission, clinic visit, and
a patient showing signs/symptoms of depression. (4)

Q19 Please write any comments or questions you may have below.
________________________________________________________________
Q20 Thank you for your valuable time and participation in my Pediatric Acute Care DNP project.
End of Block: Default Question Block
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Appendix 4. Center for Epidemiological Studies Depression Scale for Children
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